Best of ASCO - 2014 Annual Meeting

 

Welcome

Kidney Cancer

Genitourinary (Nonprostate) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.

Lorena Incorvaia

e16109

A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.

Nizar M. Tannir

TPS4595

A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).

Jianjun Gao

4501

A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).

Viktor Grünwald

e16097

A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?

Floor Lubberman

4564

A systematic review of the characteristics of thyroid metastases from clear cell renal cell carcinoma.

Karam Khaddour

e16113

Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).

Igal Kushnir

4516

Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.

David I. Quinn

4573

An estimate of premature deaths averted with immunotherapy in treating Brazilian patients with advanced clear cell renal cell carcinoma.

Gabriel Lenz

e16114

Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents.

Yasser Ged

e16103

Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.

Ugo De Giorgi

e16077

Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).

Jean-Christophe Pignon

4568

Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.

Brian I. Rini

4512

Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.

Ronan Flippot

4583

Cardiovascular mortality in renal cell carcinoma: A population-based study.

Michail Alevizakos

e16085

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Matthew Labriola

e16079

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.

David F. McDermott

4513

Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).

Ruby Gupta

e16084

Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).

Meredith M. Regan

4566

Comparative analysis of profiles of second-line stage IV renal cell carcinoma patients by first-line to second-line treatment sequencing in the United States.

Corrina DaSilva

e16110

Comparative genomic profiling from tumor tissue and circulating tumor DNA (ctDNA) in 111 patients (Pts) with metastatic clear cell renal cell carcinoma.

Ritesh Kotecha

4565

Comparison of efficacy and safety of checkpoint inhibitors in patients with genitourinary cancers aged below and above 75 years.

Gerald Bastian Schulz

e16101

Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.

Andrea Necchi

4581

Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214.

Bernard Escudier

4575

Cost-effectiveness of pazopanib as first-line treatment of metastatic renal cell carcinoma from National Health Service United Kingdom perspective.

Barbara Elizabeth Ratto

e16088

Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.

Arnaud Mejean

4508

Deep learning segmentation of kidneys with renal cell carcinoma.

Kevin Yin

e16098

Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.

Bimal Bhindi

4578

Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma.

Lucia Nappi

e16105

Dynamic contrast-enhanced MRI to predict intratumoral molecular heterogeneity in clear cell renal cell carcinoma.

Durga Udayakumar

4580

Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population.

Giuseppe Procopio

e16087

Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs).

Kirsi Manz

e16074

Efficacy and safety profile of sunitinib as a first line treatment for advanced/metastatic clear-cell renal cell carcinoma: Pooled analysis of randomized controlled trials.

Tarek Haykal

e16067

Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).

Ziad Bakouny

4514

Efficacy of receptor tyrosine kinase inhibitors (RTKIs) and immunotherapy (PD-1/PD-L1) for treatment of osseous vs. soft tissue metastases of renal cell carcinoma (RCC).

Katherine Yuxi Tai

e16094

Efficacy of systemic therapy for metastatic renal cell carcinoma in patients over 75 years of age.

Ryuichi Mizuno

e16080

Express-diagnosing of acute kidney injury among patients with the localized kidney cancer after partial nephrectomy under warm ischemia: A role of biomarkers.

Sergey N Dimitriadi

e16108

First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).

Shaan Dudani

4577

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.

Scott S. Tykodi

4570

Full adaptome repertoire analysis of immunotherapy to predict responsiveness and correlation with CD8-LAG3, sLAG3, and hepatocyte growth factor levels in patients with renal cancer.

Michael T. Lotze

e16116

Hypoxia signaling and immune infiltration in a presurgical trial of sunitinib in patients with clear cell renal cell carcinoma (RCC).

Elshad Hasanov

e16115

Immunotherapy with nivolumab in metastatic renal cell carcinoma in resource constraint settings: Impact of increasing intervals between standard doses, and stopping treatment early in responding patients.

Amit Rauthan

e16078

Impact of rural/urban residence on relative survival (RS) in patients with kidney cancer: An analysis of 14576 patients from the Austrian National Cancer Registry (ANCR).

Martin Marszalek

e16072

KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).

Jae-Lyun Lee

4569

Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.

Nirmish Singla

e16100

Long term relative survival (RS) in patients with primary metastatic kidney cancer: An analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).

Martin Marszalek

e16069

Lymphopenia and clinical significance associated with tyrosine kinase inhibitors in metastatic renal cell cancer in Guatemalan cohort.

Rixci Ramirez

e16117

Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).

Daniel Vargas Almeida

4579

Molecular profile of early-stage and advanced-stage of renal cell cancer in China.

Jimin Chen

e16071

Nivolumab in renal cancer: French evaluation of use, current practices and medico economic approach.

Francoise Grude

e16093

Novel risk stratification criteria of metastatic renal cell carcinoma (mRCC) patients (pts) treated with immune checkpoint inhibitors (ICI).

Dylan J Martini

e16068

Overall survival with or without brain metastases from diagnosis of metastatic renal cell carcinoma.

I. Alex Bowman

e16112

Pathologic response and surgical outcomes in patients undergoing nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.

Vitaly Margulis

e16102

Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in forty-three countries.

Rachel H Giles

e16091

Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).

Sumanta K. Pal

4515

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Tian Zhang

TPS4596

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Brian I. Rini

4500

Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).

Matthew R. Zibelman

4567

Prognostic and predictive biomarkers for clear cell renal cell carcinoma utilizing next generation sequencing.

Jamal Zekri

e16070

Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).

Abhishek Tripathi

4582

Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.

Kimiharu Takamatsu

e16065

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

Lauren Christine Harshman

TPS4597

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Leonard Joseph Appleman

4502

Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.

Ulas Isik

e16075

Real-world outcome study among patients with renal cell carcinoma (RCC) receiving checkpoint inhibitors (CPIs).

Hemant Phatak

e16073

Renal cell carcinoma in kidney transplant recipients at Guy’s and King’s College Hospital (UK) between 1987-2018.

Sabeeh-Ur-Rehman Butt

e16066

Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).

Nieves Martinez Chanza

4571

Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

Hamid Emamekhoo

4517

Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.

Martin Boegemann

4574

Stereotactic radiotherapy for stage I renal cell carcinoma: Overall survival and treatment trends compared to thermal ablation and surgical resection.

Annemarie Uhlig

e16111

Systematic review and network meta-analysis of first-line treatments in mRCC.

Barbara Elizabeth Ratto

e16086

Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF).

Yasser Ged

4576

The clinical outcome of renal cell carcinoma with rhabdoid and sarcomatoid differentiation.

Arash Samiei

e16083

The impact of gastric acid suppressive agents on pazopanib exposure.

Floor Lubberman

e16076

Time to surgery (TTS) in renal cell carcinoma (RCC): Predictors and association with overall survival (OS).

Anuhya Kommalapati

e16107

TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Camillo Porta

4572

Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma.

Nirmish Singla

e16096